CO2020010193A2 - Una composición farmacéutica para la anemia - Google Patents

Una composición farmacéutica para la anemia

Info

Publication number
CO2020010193A2
CO2020010193A2 CONC2020/0010193A CO2020010193A CO2020010193A2 CO 2020010193 A2 CO2020010193 A2 CO 2020010193A2 CO 2020010193 A CO2020010193 A CO 2020010193A CO 2020010193 A2 CO2020010193 A2 CO 2020010193A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
anemia
formulation
relates
aoi
Prior art date
Application number
CONC2020/0010193A
Other languages
English (en)
Inventor
Ankit Shyam Singh
Vedprakash Mishra
Neelima Tongra
Original Assignee
Frimline Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Ltd filed Critical Frimline Private Ltd
Publication of CO2020010193A2 publication Critical patent/CO2020010193A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con una composición/formulación farmacéutica para su uso en el tratamiento de la Anemia por Deficiencia de Hierro (IDA), Anemia de Inflamación (AOI) y los trastornos neurodegenerativos. De modo más específico, la invención está relacionada con una composición/formulación farmacéutica que comprende una combinación sinérgica de lactoferrina y nucleótidos de guanosina naturales o una sal farmacéuticamente aceptable de estos. La aplicación también brinda diversas formulaciones y métodos para su preparación.
CONC2020/0010193A 2018-03-09 2020-08-19 Una composición farmacéutica para la anemia CO2020010193A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821008809 2018-03-09
PCT/IB2019/051706 WO2019171236A1 (en) 2018-03-09 2019-03-04 A pharmaceutical composition for anaemia

Publications (1)

Publication Number Publication Date
CO2020010193A2 true CO2020010193A2 (es) 2020-08-31

Family

ID=66397286

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010193A CO2020010193A2 (es) 2018-03-09 2020-08-19 Una composición farmacéutica para la anemia

Country Status (24)

Country Link
US (1) US12016906B2 (es)
EP (1) EP3661373B1 (es)
AU (1) AU2019232621B2 (es)
BR (1) BR112020018319A2 (es)
CA (1) CA3073184C (es)
CO (1) CO2020010193A2 (es)
DK (1) DK3661373T3 (es)
EA (1) EA202090276A1 (es)
ES (1) ES2927216T3 (es)
HR (1) HRP20221105T1 (es)
HU (1) HUE059584T2 (es)
LT (1) LT3661373T (es)
MA (1) MA52154B1 (es)
MD (1) MD3661373T2 (es)
MY (1) MY183462A (es)
PE (1) PE20201278A1 (es)
PH (1) PH12019550263A1 (es)
PL (1) PL3661373T3 (es)
PT (1) PT3661373T (es)
RS (1) RS63563B1 (es)
SG (1) SG11202008732VA (es)
SI (1) SI3661373T1 (es)
UA (1) UA123852C2 (es)
WO (1) WO2019171236A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202020101861U1 (de) * 2020-04-06 2020-04-16 artgerecht GmbH Eisen-enthaltende Formulierung, ernährungsphysiologische Zusammensetzung, welche diese enthält, und Verwendung derselben
IT202000012373A1 (it) * 2020-05-26 2021-11-26 Prosol S P A Formulazione farmaceutica o di integratore alimentare per l’uso nel trattamento di disturbi dovuti alla carenza di ferro
IT202000022003A1 (it) * 2020-09-18 2022-03-18 Difass Int S R L Composizioni comprendenti un sale minerale per uso orale
WO2022118274A1 (en) * 2020-12-03 2022-06-09 Neilos S.r.l. Compositions for the use in the treatment and/or prevention of iron deficiency conditions or diseases
CN118524831A (zh) * 2021-12-03 2024-08-20 帝斯曼知识产权资产管理有限公司 用于维生素c的新递送系统
CN114392249B (zh) * 2022-01-13 2023-09-12 上海医药集团青岛国风药业股份有限公司 一种多糖铁复合物的肠溶微丸及粉末直压片剂
WO2024097926A1 (en) * 2022-11-03 2024-05-10 Nutrition & Biosciences Usa 1, Llc Oral biologic macromolecule delivery system
CN116530687A (zh) * 2023-06-03 2023-08-04 重庆医科大学 一种含乳酸亚铁口服溶液及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
CN1218647C (zh) 2003-04-03 2005-09-14 石家庄三鹿集团股份有限公司 新生婴儿奶粉
WO2007022537A2 (en) 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
CN102481009A (zh) 2009-08-13 2012-05-30 雀巢产品技术援助有限公司 包含外源性核苷酸的营养组合物
SG11201702036QA (en) * 2014-11-07 2017-04-27 Mjn Us Holdings Llc Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
KR20230037067A (ko) 2016-07-06 2023-03-15 빌딩 블록 뉴트리셔널즈, 엘엘씨 영양 조제식
CN106578134A (zh) 2016-12-31 2017-04-26 东北农业大学 一种预防感染性腹泻的婴儿配方奶粉
CN107549612B (zh) * 2017-09-12 2021-01-12 东北农业大学 一种提高6-12个月龄婴儿免疫力的营养配方米粉

Also Published As

Publication number Publication date
US20200405822A1 (en) 2020-12-31
PE20201278A1 (es) 2020-11-24
HUE059584T2 (hu) 2022-11-28
MY183462A (en) 2021-02-18
HRP20221105T1 (hr) 2022-11-25
PH12019550263A1 (en) 2021-01-11
WO2019171236A1 (en) 2019-09-12
AU2019232621A1 (en) 2020-03-12
RS63563B1 (sr) 2022-10-31
CA3073184C (en) 2021-11-16
EA202090276A1 (ru) 2020-11-16
PL3661373T3 (pl) 2022-10-03
MD3661373T2 (ro) 2022-11-30
PT3661373T (pt) 2022-09-22
BR112020018319A2 (pt) 2020-12-29
SI3661373T1 (sl) 2022-10-28
EP3661373B1 (en) 2022-06-22
MA52154B1 (fr) 2022-09-30
EP3661373A1 (en) 2020-06-10
SG11202008732VA (en) 2020-10-29
AU2019232621B2 (en) 2020-10-08
UA123852C2 (uk) 2021-06-09
MA52154A (fr) 2020-06-10
LT3661373T (lt) 2022-09-26
ES2927216T3 (es) 2022-11-03
US12016906B2 (en) 2024-06-25
CA3073184A1 (en) 2019-09-12
DK3661373T3 (da) 2022-09-12

Similar Documents

Publication Publication Date Title
CO2020010193A2 (es) Una composición farmacéutica para la anemia
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
SV2018005778A (es) Derivados aromaticos de sulfonamida
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
PH12018502634A1 (en) Topical compositions of apremilast
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
UY37098A (es) Moduladores de ror-gamma
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
EA201990820A1 (ru) Способы лечения митохондриальных и метаболических нарушений
PH12019550249A1 (en) Solid compositions for oral administration
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2021004517A (es) Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2021000930A1 (es) Piridazinas novedosas
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP20044715A (es) Una composición farmacéutica para la anemia
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease